• Blog
  • California Consumer Privacy Act (CCPA)
  • Cart
  • Checkout
  • Contact
  • DMCA
  • Home
  • My account
  • Privacy Policy
  • Shop
Monday, October 27, 2025
  • Login
Buyer's Insight
  • Home
  • Top Stories
  • Local News
    • Politics
    • Business & Economy
    • Entertainment
    • Sports
  • Health
  • Lifestyle
  • Science & Environment
  • Technology
  • Review Radar
    • Weight Loss Products Reviews
    • Forex Trading
    • Shop
  • Contact
No Result
View All Result
  • Home
  • Top Stories
  • Local News
    • Politics
    • Business & Economy
    • Entertainment
    • Sports
  • Health
  • Lifestyle
  • Science & Environment
  • Technology
  • Review Radar
    • Weight Loss Products Reviews
    • Forex Trading
    • Shop
  • Contact
No Result
View All Result
Buyer's Insight
No Result
View All Result

Zydus Lifesciences obtains a sign of Health Canada for Liothyronine Tablets

Michael Johnson by Michael Johnson
October 7, 2025
in Business & Economy
Reading Time: 2 mins read
0
0
SHARES
0
VIEWS
Zydus Lifesciences LTD said on Monday that he had received a COMPANITY COMPLOSITY (NOC) of Health Canada for his generic LITHYRININE tablets in 5 mcg and 25 mcg.

Liothyronine, a synthetic form of T3 thyroid hormone (triiodothyronin), is mainly used to treat hypothyroidism. The tablets will be made in the installation of Zydus Ahmedabad Sez.

The product made annual sales of $ 10.9 million Canadian dollars in Canada, according to IQVIA MAT data for June 2025.

Zydus, including its subsidiaries and affiliates, said that approval will allow it to market the drug in Canada, expanding its footprint on the North American generic market. Zydus Lifesciences Limited is a diversified Indian Pharmaceutical Company engaged in the research, development, manufacturing and marketing of a wide range of health products. Its portfolio covers brand formulations, generics, biosimilars, active pharmaceutical ingredients (API), vaccines and over -the -counter products.

Based in Ahmedabad, the company operates worldwide, with a strong presence in North America, Europe and emerging markets.

Read also: Zydus Life Q1 Results: Fy26 Guide maintained, but actions fall under moderate gains

In a separate announcement, Zydus said it had obtained the final approval of the US Food and Drug Administration (USFDA) for the DEFLAZACORT oral suspension, 22.75 mg / ml, a generic version of the Emflaza oral suspension.

Steroid medication is used to treat Duchenne muscular dystrophy (DMD) in patients aged five and over, helping to reduce inflammation and modulate a hyperactive immune response. Zydus will make the product in its doppel installation in Italy. With this latest approval, the group’s cumulative approvals of the group reach 424, out of 487 new abbreviated medication requests (Andas) since it entered the submission in 2003-04.

The actions of Zydus Lifesciences Ltd ended at 994.55 ₹, up 5.80 ₹, or 0.59%, on the ESB.

Posted for the first time: October 6, 2025 5:59 p.m. It

Source link

Post Views: 0
Tags: CanadahealthLifesciencesLiothyronineobtainssignTabletsZydus
Previous Post

The dodgers have survived the phillies, take the commanding lead of 2-0 NLDs

Next Post

Hundreds of migrants set up a demonstration in southern Mexico in order to legalize the status

Related Posts

Business & Economy

Federal health insurance premiums will see another significant increase in 2026

October 10, 2025
Business & Economy

ONGC to provide first guarantee in 15 years for unit bond sale, says report

October 10, 2025
Business & Economy

US opens investigation into Tesla after new accidents involving its self-driving technology

October 9, 2025
Business & Economy

Levi Strauss (LEVI) Third Quarter 2025 Results

October 9, 2025
Business & Economy

Trump Administration Sends Student Loan Cancellation Notices

October 9, 2025
Business & Economy

Asia Economic Calendar October 10, 2025 – RBA’s Bullock and Fed’s Daly speak

October 9, 2025
Next Post

Hundreds of migrants set up a demonstration in southern Mexico in order to legalize the status

Zoma News Pulse

  • Home
  • California Consumer Privacy Act (CCPA)
  • Contact
  • DMCA
  • Privacy Policy

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Top Stories
  • Local News
    • Politics
    • Business & Economy
    • Entertainment
    • Sports
  • Health
  • Lifestyle
  • Science & Environment
  • Technology
  • Review Radar
    • Weight Loss Products Reviews
    • Forex Trading
    • Shop
  • Contact